STOCK TITAN

[Form 4] Mr. Cooper Group Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.

  • Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
  • Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
  • No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.

The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.

Il modulo 4 per UnitedHealth Group (UNH) datato 02/07/2025 rivela la consueta compensazione azionaria trimestrale a favore del direttore non dipendente Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità azionarie differite (immediatamente maturate, da mantenere fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in altri due trust, per un totale di 2.246 azioni detenute indirettamente.
  • Non sono stati acquisiti né ceduti titoli derivati; la comunicazione indica che i premi sono compensazioni ordinarie trimestrali per il direttore, non incentivi o acquisti di mercato.

La comunicazione è di natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment interno oltre alla consueta remunerazione del consiglio.

El formulario 4 de UnitedHealth Group (UNH) fechado el 02/07/2025 revela la compensación trimestral habitual en acciones al director externo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (consolidado inmediatamente, deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones ordinarias, ambas otorgadas a costo cero.
  • Propiedad después de la transacción: 2.750 acciones ordinarias en propiedad directa; 2.146 acciones en un fideicomiso revocable; 45 y 55 acciones en otros dos fideicomisos, sumando un total de 2.246 acciones en propiedad indirecta.
  • No se adquirieron ni vendieron valores derivados; la presentación indica que los premios son compensación trimestral regular para el director, no incentivos ni compras de mercado.

La presentación es de carácter administrativo, sin impacto en las operaciones de la empresa, estructura de capital o sentimiento interno más allá de la compensación habitual del consejo.

2025년 7월 2일자 UnitedHealth Group (UNH) Form 4 제출서류는 비임원 이사 Paul R. Garcia에 대한 정기 분기별 주식 보상을 공개합니다.

  • 거래 내역 (2025년 7월 1일): 173개의 이연 주식 단위(즉시 취득, 이사회 임기 종료 시까지 보유해야 함)와 96주의 보통주가 각각 비용 없이 부여되었습니다.
  • 거래 후 보유 현황: 직접 보유한 보통주 2,750주; 취소 가능한 신탁에 2,146주; 두 개의 추가 신탁에 각각 45주와 55주, 총 간접 보유 2,246주.
  • 파생 증권의 취득 또는 처분은 없었으며, 제출서류는 이 보상이 인센티브나 시장 매입이 아닌 정기적인 분기별 이사 보상임을 명시합니다.

이 제출은 행정적인 성격이며, 회사 운영, 자본 구조, 내부자 심리에 관해 관례적인 이사회 보상을 넘어서는 영향은 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle une rémunération trimestrielle habituelle en actions pour le directeur non salarié Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d'actions différées (acquises immédiatement, doivent être conservées jusqu'à la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, pour un total de 2 246 actions détenues indirectement.
  • Aucun titre dérivé n'a été acquis ou cédé ; le dépôt indique que les attributions sont une rémunération trimestrielle régulière du directeur, non basées sur des incitations ni des achats sur le marché.

Le dépôt est de nature administrative, sans impact sur les opérations de l'entreprise, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 legt die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia offen.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktieneinheiten (sofort unverfallbar, müssen bis zum Ende der Vorstandszugehörigkeit gehalten werden) und 96 Stammaktien, beide zu Nullkosten gewährt.
  • Eigentum nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 Aktien indirekt gehalten.
  • Es wurden keine Derivate erworben oder veräußert; die Einreichung beschreibt die Zuwendungen als reguläre vierteljährliche Direktorenvergütung, keine leistungsabhängigen oder marktbezogenen Käufe.

Die Einreichung ist administrativer Natur und hat keinen Einfluss auf die Unternehmensführung, Kapitalstruktur oder Insider-Stimmung über die übliche Vorstandsvergütung hinaus.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; neutral for valuation.

The reported acquisitions are standard board compensation—non-cash and immaterial relative to UNH’s 930 million shares outstanding. The director’s aggregate direct stake (≈0.0003%) remains negligible, offering no meaningful signal of insider conviction or strategy shift. No derivatives, sales, or large block moves were disclosed, and there is no indication of upcoming corporate events. Consequently, the filing should be viewed as housekeeping rather than a catalyst.

TL;DR: Confirms UNH’s standard board pay structure; no red flags.

The grant aligns with prevailing S&P 500 director pay practice of quarterly stock/DSU awards to foster alignment with shareholders. Mandatory deferral of DSUs until board departure supports long-term oversight. No unusual acceleration clauses or special awards appear, indicating consistent, transparent governance. The filing poses no governance concerns and is non-impactful to investors.

Il modulo 4 per UnitedHealth Group (UNH) datato 02/07/2025 rivela la consueta compensazione azionaria trimestrale a favore del direttore non dipendente Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità azionarie differite (immediatamente maturate, da mantenere fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in altri due trust, per un totale di 2.246 azioni detenute indirettamente.
  • Non sono stati acquisiti né ceduti titoli derivati; la comunicazione indica che i premi sono compensazioni ordinarie trimestrali per il direttore, non incentivi o acquisti di mercato.

La comunicazione è di natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment interno oltre alla consueta remunerazione del consiglio.

El formulario 4 de UnitedHealth Group (UNH) fechado el 02/07/2025 revela la compensación trimestral habitual en acciones al director externo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (consolidado inmediatamente, deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones ordinarias, ambas otorgadas a costo cero.
  • Propiedad después de la transacción: 2.750 acciones ordinarias en propiedad directa; 2.146 acciones en un fideicomiso revocable; 45 y 55 acciones en otros dos fideicomisos, sumando un total de 2.246 acciones en propiedad indirecta.
  • No se adquirieron ni vendieron valores derivados; la presentación indica que los premios son compensación trimestral regular para el director, no incentivos ni compras de mercado.

La presentación es de carácter administrativo, sin impacto en las operaciones de la empresa, estructura de capital o sentimiento interno más allá de la compensación habitual del consejo.

2025년 7월 2일자 UnitedHealth Group (UNH) Form 4 제출서류는 비임원 이사 Paul R. Garcia에 대한 정기 분기별 주식 보상을 공개합니다.

  • 거래 내역 (2025년 7월 1일): 173개의 이연 주식 단위(즉시 취득, 이사회 임기 종료 시까지 보유해야 함)와 96주의 보통주가 각각 비용 없이 부여되었습니다.
  • 거래 후 보유 현황: 직접 보유한 보통주 2,750주; 취소 가능한 신탁에 2,146주; 두 개의 추가 신탁에 각각 45주와 55주, 총 간접 보유 2,246주.
  • 파생 증권의 취득 또는 처분은 없었으며, 제출서류는 이 보상이 인센티브나 시장 매입이 아닌 정기적인 분기별 이사 보상임을 명시합니다.

이 제출은 행정적인 성격이며, 회사 운영, 자본 구조, 내부자 심리에 관해 관례적인 이사회 보상을 넘어서는 영향은 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle une rémunération trimestrielle habituelle en actions pour le directeur non salarié Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d'actions différées (acquises immédiatement, doivent être conservées jusqu'à la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, pour un total de 2 246 actions détenues indirectement.
  • Aucun titre dérivé n'a été acquis ou cédé ; le dépôt indique que les attributions sont une rémunération trimestrielle régulière du directeur, non basées sur des incitations ni des achats sur le marché.

Le dépôt est de nature administrative, sans impact sur les opérations de l'entreprise, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 legt die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia offen.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktieneinheiten (sofort unverfallbar, müssen bis zum Ende der Vorstandszugehörigkeit gehalten werden) und 96 Stammaktien, beide zu Nullkosten gewährt.
  • Eigentum nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 Aktien indirekt gehalten.
  • Es wurden keine Derivate erworben oder veräußert; die Einreichung beschreibt die Zuwendungen als reguläre vierteljährliche Direktorenvergütung, keine leistungsabhängigen oder marktbezogenen Käufe.

Die Einreichung ist administrativer Natur und hat keinen Einfluss auf die Unternehmensführung, Kapitalstruktur oder Insider-Stimmung über die übliche Vorstandsvergütung hinaus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bray Jesse K

(Last) (First) (Middle)
8950 CYPRESS WATERS BLVD.

(Street)
COPPELL TX 75019

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mr. Cooper Group Inc. [ COOP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 S 30,000(1) D $152.14(2) 693,187 I By The Jesse K. Bray Living Trust
Common Stock 198,398 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a previously announced Rule 10b5-1 trading plan adopted by the Jesse K. Bray Living Trust (the "Trust") on June 13, 2024.
2. The price reported in Column 4 is a weighted average price; the shares were sold in multiple transactions at prices ranging from $149.51 to $154.12, inclusive. Reporting Person, on behalf of the Trust, undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Remarks:
/s/Katherine K. Connell, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group shares did Paul R. Garcia acquire on 07/01/2025?

He received 96 shares of common stock and 173 deferred stock units as part of quarterly board compensation.

What is Paul R. Garcia’s total direct ownership in UNH after the transaction?

Following the award, he directly holds 2,750 common shares of UnitedHealth Group.

Are the deferred stock units (DSUs) immediately vested?

Yes. The DSUs vest immediately but must be held until the director’s service on the board ends.

Did the filing disclose any insider sales or derivative transactions?

No. The Form 4 reports only acquisitions of stock and DSUs; no sales or derivative activity were reported.

Does this Form 4 filing affect UnitedHealth Group’s share count?

No. The awards are sourced from the company’s existing equity compensation plan and do not materially alter the total shares outstanding.
Mr Cooper Group Inc

NASDAQ:COOP

COOP Rankings

COOP Latest News

COOP Stock Data

9.69B
62.62M
3.62%
94.83%
3.02%
Mortgage Finance
Finance Services
Link
United States
COPPELL